BioMedNewsBreaks

FridayDec 20, 2024 3:12 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Committed to Ensuring Highest Standards in Continued Buntanetap Trials

Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases. The company’s lead candidate, buntanetap, is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression. A recent article highlights the company’s successful clinical trials and its receipt of FDA clearance to proceed with a pivotal phase 3 Alzheimer’s disease program for buntanetap, set to begin in early 2025. “Our priority is to bring a safe and effective treatment to patients, and we are…

Continue Reading

ThursdayDec 19, 2024 10:33 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Secures $10 Million Debt Facility to Advance Neurodegenerative Disease Treatments

Clene (NASDAQ: CLNN) has announced a $10 million debt facility with three affiliated entities, set to close by December 20, 2024. The 18-month secured, partially convertible note carries a 12% fixed interest rate, with an interest-only period for the first year. Sixty-five percent of the note is convertible into common stock at $5.67 per share, a 130% premium over the stock’s signing day closing price. Proceeds will support Clene’s development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, addressing FDA data requirements for regulatory approval. The company also aims to repay its prior $7.9 million Loan Agreement with Avenue Venture…

Continue Reading

WednesdayDec 18, 2024 3:02 pm

BioMedNewsBreaks — Lantern Pharma Inc. (LTRN) Expands HARMONIC™ Trial to Asia with First Patient Dosed in Taiwan

Lantern Pharma (LTRN)  has enrolled and dosed its first patient in Taiwan for the Phase 2 HARMONIC™ trial evaluating LP-300 in never-smokers with non-small cell lung cancer (“NSCLC”) who have relapsed after tyrosine kinase inhibitor (“TKI”) treatment. This expansion into Asia addresses the region's higher prevalence of never-smoker NSCLC cases, with Taiwan being a key area as over half of lung cancer diagnoses there occur in never-smokers. The trial, conducted across sites in the U.S., Japan, and Taiwan, aims to enroll 90 patients to assess progression-free survival (“PFS”) and overall survival (“OS”) outcomes. Lantern highlighted promising preliminary results, including an…

Continue Reading

TuesdayDec 17, 2024 10:33 am

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Launches $2 Million Share Repurchase Program Amid Record Revenue Growth

NextPlat (NASDAQ: NXPL, NXPLW) announced its Board of Directors has approved a share repurchase program of up to $2 million in outstanding common stock. The timing and execution of repurchases will be at the Company's discretion, with flexibility to utilize open market or privately negotiated transactions. NextPlat expects to achieve record 2024 annual revenue exceeding $63 million, a 70% increase over 2023, driven by growth in satellite connectivity products, recurring airtime revenue, and healthcare contributions. CEO Charles M. Fernandez emphasized the company’s focus on double-digit revenue growth and positive operating cashflows in 2025, supported by a strong balance sheet, as…

Continue Reading

MondayDec 16, 2024 1:55 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Eyes Clear Path Forward for Buntanetap

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s (“AD”) and Parkinson’s (“PD”). The company concluded the third quarter with the completion of significant milestones and a clear path forward for its lead candidate, buntanetap. “Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43,” reads a recent article. “This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying, positioning buntanetap as a potential breakthrough in treating neurodegenerative diseases.”…

Continue Reading

MondayDec 16, 2024 11:01 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary

Scinai Immunotherapeutics (NASDAQ: SCNI) has established a U.S.-based subsidiary, Scinai Bioservices Inc., to enhance its Contract Development and Manufacturing Organization (CDMO) operations and address the growing demand for early-stage biologics development in the U.S. Operating from a cGMP-compliant facility in Jerusalem, Israel, Scinai Bioservices has supported nine biotech companies since its 2024 launch and recently signed its first U.S. customer, Serpin Pharma. The new subsidiary will provide boutique CDMO services tailored to early-stage biotech startups, leveraging U.S. grant funding opportunities while addressing concerns related to the BIOSECURE Act. Scinai anticipates significant growth in its CDMO revenues and reputation in the…

Continue Reading

MondayDec 16, 2024 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA Clearance for Innovative Arrhythmia Assessment Device

HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its groundbreaking HeartBeam system, a credit card-sized, cable-free ECG device designed for comprehensive arrhythmia assessment. The system enables patients to record high-fidelity heart signals from three directions during symptoms, with data transmitted to physicians for timely review and action. This milestone marks the first FDA-cleared device of its kind and lays the foundation for future advancements, including synthesized 12-lead ECGs, AI-driven arrhythmia detection, and heart attack risk assessment. HeartBeam aims to transform cardiac care by delivering actionable insights and predictive diagnostics for patients and physicians globally. To view the full press…

Continue Reading

FridayDec 13, 2024 3:08 pm

BioMedNewsBreaks — Jackson Acquisition Company II (NYSE: JACS.U) Announces Closing of IPO

Jackson Acquisition Company (NYSE: JACS.U) has closed its initial public offering of 23,000,000 units at $10.00 per unit. According to the announcement, the offering size reflects the full exercise of the underwriter’s over-allotment option. The units began trading on the New York Stock Exchange under the ticker symbol JACS.U on Dec. 10, 2024. Each unit consists of one Class A ordinary share and one right to receive one-tenth (1/10) of a Class A ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are…

Continue Reading

ThursdayDec 12, 2024 1:47 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) at the Forefront of Cancer Treatment Innovation

Calidi Biotherapeutics (NYSE American: CLDI) was featured in a recent article that showcased the company as a compelling example of progress of emerging therapies and advances that are reshaping the fight against cancer. Calidi’s “recent data on its RTNova(TM) systemic enveloped virotherapy technology demonstrates the potential of cutting-edge solutions to revolutionize cancer care,” the article reads. “At two major conferences—the International Oncolytic Virotherapy Conference (‘IOVC’) and the Society for Immunotherapy of Cancer (‘SITC’) Annual Meeting—Calidi presented groundbreaking data supporting the capabilities of its proprietary RTNova systemic enveloped virotherapy platform. RTNova is designed to address the limitations of traditional virotherapy by offering…

Continue Reading

ThursdayDec 12, 2024 12:04 pm

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies

Telomir Pharmaceuticals (NASDAQ: TELO) has raised $1 million in equity funding from The Starwood Trust through a common stock transaction priced at $7 per share, a 20% premium to the closing price. This follows an undrawn $5 million non-dilutive line of credit from The Starwood Trust earlier this year, reinforcing confidence in Telomir’s strategy. The funding supports Telomir’s innovative pipeline, led by its breakthrough compound, Telomir-1, which has demonstrated preclinical efficacy in reversing age-related conditions, including Type 2 diabetes, by addressing root causes like oxidative stress and telomere shortening. Telomir is also advancing research in Alzheimer’s, cancer, osteoarthritis, and Wilson…

Continue Reading